Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.70 |
| ▸ | HEXA | P06865 | 1/20 | 0.70 |
| ▸ | HEXB | P07686 | 1/20 | 0.70 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.64 |
| ▸ | GLS | O94925 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973833 | 0.98 | OGA (0.68) | OGAHEXAHEXBSIRT1GLS | |
| SCHEMBL7476248 | 0.92 | SIRT1 (0.66) | OGAHEXAHEXBSIRT1ACHE | |
| SCHEMBL28437687 | 0.91 | HEXA (0.60) | OGAHEXAHEXBSIRT1GLS | |
| SCHEMBL3197666 | 0.91 | TERT (0.67) | OGAHEXAHEXBSIRT1GLS | |
| Acetic Acid SCHEMBL4521454 | 0.89 | OGA (0.58) | OGAHEXAHEXBSIRT1ACHE | |
| SCHEMBL20818051 | 0.89 | ALDH1A1 (0.59) | OGAHEXAHEXBSIRT1GLS | |
| SCHEMBL1210939 | 0.88 | OGA (0.57) | OGAHEXAHEXBSIRT1GLS | |
| SCHEMBL9218494 | 0.88 | ACHE (0.66) | SIRT1ACHE | |
| SCHEMBL10282631 | 0.88 | SIRT1 (0.60) | OGAHEXAHEXBSIRT1ACHE | |
| SCHEMBL18730546 | 0.88 | TDP1 (0.61) | OGAHEXAHEXBSIRT1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511035-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-03-31 | — | — | US | claimed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | claimed |
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2003518131-A | — | — | 2003-06-03 | — | — | JP | claimed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | claimed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | claimed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | claimed |
| US-11795247-B2 | Polyolefin dispersants and methods of making and using thereof | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220025254-A1 | Complexes and Ligands | THE GENERAL HOSPITAL CORPORATION | 2022-01-27 | — | — | US | disclosed |
| WO-2021047139-A1 | POLYAMINO SURFACTANT, PREPARATION METHOD THEREFOR AND USE THEREOF | 肯特催化材料股份有限公司 | 2021-03-18 | — | — | WO | disclosed |
| EP-3229848-B1 | TARGETED CONTRAST AGENTS COMPRISING A HYDRAZIDE FUNCTIONAL GROUP | RF THERAPEUTICS INC (CA) | 2020-08-12 | — | — | EP | disclosed |
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | RF THERAPEUTICS INC. (CA) | 2019-05-14 | — | — | US | disclosed |
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | RF THERAPEUTICS INC. (CA) | 2019-05-14 | — | — | US | disclosed |
| WO-1989012631-A1 | MACROCYCLIC BIFUNCTIONAL CHELANTS, COMPLEXES THEREOF AND THEIR ANTIBODY CONJUGATES | THE DOW CHEMICAL COMPANY (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4837003-A | RADIONUCLIDE-ANTIBODY CHELATE COMPLEX; TUMOR DIAGNOSIS | MALLINCKRODT, INC. (US) | 1989-06-06 | — | — | US | disclosed |
| US-4659839-A | MALEIMIDE AND CHELATING MOIETY | MALLINCKRODT, INC. (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0194750-A1 | Dihydropyridine alkanol amines, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-17 | — | — | EP | disclosed |
| WO-1986004581-A1 | DIHYDROPYRIDINE ALKANOLAMINES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-08-14 | — | — | WO | disclosed |
| EP-0178125-A2 | Labeled antibody fragments. | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0174853-A2 | Radiolabeled antibody fragments | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | ANTXR2, CA4, CA14 | OGA 1049/4885HEXA 325/4885HEXB 419/4885 |
| US-20080139539-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | OGA 2721/4885HEXA 1349/4885HEXB 2133/4885 |
| US-20220025254-A1 | Complexes and Ligands | BID, CLTB, NECTIN4 | OGA 1829/4885HEXA 2320/4885HEXB 1628/4885 |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | MPI, SLC39A14, LRPPRC | OGA 2648/4885HEXA 2812/4885HEXB 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.